Tag: nasdaq:tyme

September 25, 2019

TYME Launches TYME-88-PANC Trial

The company's TYME-99-Panc trial will evaluate its candidate SM-88 in patients with metastatic pancreatic cancer.
July 7, 2019

5 Top Weekly NASDAQ Biotech & Pharma Stocks: Corvus Soars

Which companies were on the rise last week? We take a look at the top five biotech and pharma stocks...
July 5, 2019

TYME Provides Updated Data on TYME-88-Panc Phase II Study

Tyme Technologies (NASDAQ:TYME) has provided an update on its open-label Phase 2 TYME-88-Panc study. As quoted in the press release:...
April 3, 2019

TYME Secures Capital to Advance Pivotal Studies of SM-88 in Metastatic Pancreatic Cancer

Tyme Technologies (NASDAQ:TYME) has announced the closing of an underwritten registered offering with three existing investors and one new investor...
February 25, 2019

TYME Receives FDA Guidance on Pivotal Trial for SM-88 in Treatment for Advanced Pancreatic Cancer

Tyme Technologies (NASDAQ:TYME) has announced it has received design guidance for a registrational trial from the US Food and Drug...
January 18, 2019

TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study

Tyme Technologies (NASDAQ:TYME), an emerging biotechnology company developing metabolic-based cancer therapies announces that an open label phase II clinical trial...
December 2, 2018

5 Top Weekly NASDAQ Biotech Stocks: Arsanis Gains 271 Percent

Arsanis, Tyme Technologies, CohBar, Cocrystal Pharma and Contrafect were last week's top gainers.